{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T02:26:20Z","timestamp":1784168780909,"version":"3.55.0"},"reference-count":19,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2011,9,16]],"date-time":"2011-09-16T00:00:00Z","timestamp":1316131200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Psoriasis patients who are treated with tumour necrosis factor (TNF)\u2010alpha antagonists are at increased risk of reactivation of latent tuberculosis infection (LTBI) and should be adequately screened and monitored during active treatment.<\/jats:p><jats:p><jats:bold>Objectives\u2002<\/jats:bold> To evaluate in a prospective study, the performance of Quantiferon\u2010TB\u2010Gold in tube (QFT) <jats:italic>in vitro<\/jats:italic> assay compared to the conventional tuberculin skin test (TST) in detecting LTBI among a cohort of non\u2010BCG\u2010vaccinated patients with moderate\u2010to\u2010severe psoriasis during long\u2010term treatment (12\u2003months) with TNF\u2010alpha antagonists.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> A total of 50 patients underwent QFT and TST testing at baseline and after 6 and 12\u2003months of continuous anti\u2010TNF\u2010alpha treatment. Diagnosis of LTBI was made on the basis of a positive QFT result and negative chest\u2010radiographic and microbiological assays. Patients with LTBI were subjected to standard isoniazid chemoprophylaxis and after 1\u2003month, they resumed anti\u2010TNF\u2010alpha treatment with subsequent QFT and TST testing after 6\u2003months. In all the cases, a follow\u2010up period of 12\u2003months was observed.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> During the 12\u2010month\u2010study period, 14% of patients presented a QFT conversion. During active anti\u2010TNF\u2010alpha treatment, a QFT conversion was observed in 10% of patients (five cases). Agreement between QFT and TST was moderate (\u03ba\u2003=\u20030.408) at screening, good (\u03ba\u2003=\u20030.734) after 6\u2003months and fair (\u03ba\u2003=\u20030.328) after 12\u2003months of treatment. A total of 18% of patients presented a positive, discordant TST during the study period.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> A single\u2010test QFT\u2010based screening strategy for LTBI in psoriasis patients receiving long\u2010term anti\u2010TNF\u2010alpha treatment could reduce the incidence of false\u2010positive LTBI cases, preventing unnecessary TB chemoprophylaxis.<\/jats:p>","DOI":"10.1111\/j.1468-3083.2011.04220.x","type":"journal-article","created":{"date-parts":[[2011,9,16]],"date-time":"2011-09-16T19:26:24Z","timestamp":1316201184000},"page":"1572-1576","source":"Crossref","is-referenced-by-count":37,"title":["Clinical applicability of Quantiferon\u2010TB\u2010Gold testing in psoriasis patients during long\u2010term anti\u2010TNF\u2010alpha treatment: a prospective, observational study"],"prefix":"10.1111","volume":"26","author":[{"given":"S.","family":"Garcovich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ruggeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"D\u2019Agostino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Ardito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"De Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Delogu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Fadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,9,16]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-0366"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09505.x"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.10028.x"},{"key":"e_1_2_5_5_2","article-title":"Controlling tuberculosis in the United States: recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America","volume":"54","author":"Centers for Disease Control and Prevention","year":"2005","journal-title":"MMWR"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200402-179OC"},{"key":"e_1_2_5_7_2","first-page":"126","article-title":"Tuberculosis and opportunistic infections: relevance to biologic agents","volume":"22","author":"Bieber J","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(08)70227-5"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-149-3-200808050-00241"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00115110"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03389.x"},{"key":"e_1_2_5_12_2","volume-title":"Tuberculosis: Clinical diagnosis and management of tuberculosis, and measures for its prevention and control [Internet]","author":"National Collaborating Centre for Chronic Conditions (UK)","year":"2006"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00017807"},{"key":"e_1_2_5_14_2","unstructured":"World Health Organization: tuberculosis country profile \u2013 Italy. URLhttps:\/\/extranet.who.int\/sree\/Reports?op=Replet&name=%2FWHO_HQ_Reports%2FG2%2FPROD%2FEXT%2FTBCountryProfile&ISO2=IT&outtype=html(last accessed 15 April 2011)."},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09331.x"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.10137.x"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1159\/000222431"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1106"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200511-1783OC"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00005-10"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2011.04220.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2011.04220.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T08:38:19Z","timestamp":1697359099000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2011.04220.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,16]]},"references-count":19,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["10.1111\/j.1468-3083.2011.04220.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2011.04220.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,16]]}}}